SCHEMBL6146444

SCHEMBL6146444

CSC1(SC)CCOc2ccc(CC(=O)O)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP26A1 O43174 2/20 0.50
CYP26B1 Q9NR63 1/20 0.50
AKR1B1 P15121 2/20 0.42
RAB9A P51151 2/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 2/20 0.39
GAA P10253 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
ALOX15 P16050 1/20 0.39
HTT P42858 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
CA2 P00918 1/20 0.37
RARA P10276 1/20 0.37
RARB P10826 1/20 0.37
RARG P13631 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6670288 0.82 CYP26A1 (0.39) CYP26A1CYP26B1AKR1B1RARARARB
SCHEMBL6146899 0.82 CYP26A1 (0.69) CYP26A1CYP26B1AKR1B1RXRARXRB
SCHEMBL6017429 0.81 CHRM2 (0.35) CYP26A1CYP26B1AKR1B1RARARARB
SCHEMBL28840697 0.81 CYP26A1 (0.51) CYP26A1CYP26B1AKR1B1RAB9AALDH1A1
SCHEMBL8101913 0.80 RARB (0.53) CYP26A1CYP26B1AKR1B1ALDH1A1RXRA
SCHEMBL8109801 0.80 CYP26A1 (0.46) CYP26A1CYP26B1AKR1B1RAB9AALDH1A1
SCHEMBL1162271 0.79 CYP26A1 (0.50) CYP26A1CYP26B1AKR1B1RAB9AALDH1A1
SCHEMBL9817676 0.78 FFAR1 (0.47)
SCHEMBL30148890 0.77 CYP26A1 (0.48) CYP26A1CYP26B1AKR1B1RAB9AALDH1A1
SCHEMBL4421853 0.77 KDM4E (0.50) CYP26A1CYP26B1AKR1B1RAB9ARXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1280757-B1 NEW GAMMA SELECTIVE RETINOIDS HOFFMANN LA ROCHE (CH) 2005-08-17 EP disclosed
US-6603012-B2 RAR selective retinoid agonists HOFFMANN-LA ROCHE INC. 2003-08-05 US disclosed
EP-1280757-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-05 EP disclosed
US-20020026060-A1 RAR selective retinoid agonists F.HOFFMANN-LA ROCHE AG (CH) 2002-02-28 US disclosed
WO-2001083438-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020026060-A1 RAR selective retinoid agonists RARA, RARG, RARB CYP26A1 474/4885CYP26B1 923/4885AKR1B1 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.